Ceftazidime is a parenteral cephalosporin frequently used in pregnant women for treatment of urinary tract or intrauterine infections. Despite its regular use in pregnant women, ceftazidime disposition in both mother and fetus is not well understood, and a pharmacokinetic (PK) model that allows characterization and simulation of both maternal and preterm neonatal ceftazidime disposition is not available. In this study, 10 pregnant women with suspected or proven intrauterine infections in the late second and early third trimester were treated with 1 g of ceftazidime intravenously every 6 hours. During ceftazidime treatment, one maternal and umbilical cord blood sample was taken at delivery to quantify ceftazidime concentrations in the mother and preterm neonate. Data showed that ceftazidime concentrations in the mother were comparable to those observed in the neonate. Based on these data, a PK model was developed to describe maternal disposition, ceftazidime distribution over the placenta, and elimination in the neonate. The maternal substructure of the model was parameterized according to a previously reported ceftazidime model with minor adjustments to account for pregnancy-related effects on renal elimination of ceftazidime. The expanded population PK model with an additional neonatal compartment was fitted to measured drug concentrations in the neonate. The neonatal elimination rate constant at delivery was close to that estimated for the mother. The presented results show that ceftazidime readily crosses the placenta and indicate that perinatal PK behavior of ceftazidime in preterm neonates can be expected to be similar to those observed in their mothers.
Ceftazidime is a third-generation, parenteral cephalosporin with antibiotic activity against a number of pathogens, including Escherichia coli, Neisseria meningitidis, Neisseria gonorrhoeae, and Streptococcus agalactiae (group B streptococcus). In pregnant women, ceftazidime is frequently used for the treatment of urinary tract or intrauterine infections. If untreated, urinary tract infections may progress to pyelonephritis, 1 which is strongly associated with preterm delivery and low birth weight. 2, 3 Intrauterine infections also pose deleterious effects to the fetus. It has been observed that intrauterine infections are a substantial risk factor for preterm delivery 4 and fetal lung injury, which may lead to chronic lung disease. 5 As a hydrophilic compound, ceftazidime is vastly distributed to tissues with high water content, such as muscle and kidneys, with minimal intracellular penetration. 6, 7 Protein binding of ceftazidime is rather low (ß21% are bound). 8 In adults, ceftazidime is rapidly and almost exclusively eliminated as unchanged drug via the kidneys. Less than 1% of the administered dose undergoes biliary excretion. 9, 10 Glomerular filtration has been identified as the sole pathway of renal excretion in adults, 11 while a small fraction may also be excreted via tubular secretion in preterm neonates. 12 Despite its frequent use, the pharmacokinetics (PK) of ceftazidime in both pregnant women and their unborn children has not been extensively characterized. In a previous study, the pattern of ceftazidime clearance in pregnant women was unaltered compared to nonpregnant adults, but, as a consequence of the higher glomerular filtration rate, the renal excretion during pregnancy was increased. 13 Fetal exposure, though, was not addressed in this study. Other studies investigated the transfer of ceftazidime over the placental barrier in the first, 14 second, 15 and late third trimester of pregnancy. 16 In all three studies, it was observed that ceftazidime readily crosses the placenta, achieving levels in the amniotic fluid that were comparable or exceeding those observed in the maternal plasma. While these studies generated important insights in fetomaternal ceftazidime PK, no PK model has been published to date that allows characterization and simulation of coupled maternal and neonatal ceftazidime PK behavior. Therefore, the purpose of this study was to develop a PK model for ceftazidime on the basis of concentration data collected in pregnant women and their newborns at delivery.
Methods
The study protocol for the clinical study included in this analysis was approved by the Medical Ethical Committee of the University Hospital Rotterdam. All women provided written informed consent for themselves and both parents provided written informed consent for the neonate.
Patients and Study Design
This was a prospective, single-center study. Pregnant women admitted to the Department of Obstetrics of the Erasmus Medical Center in Rotterdam, the Netherlands, with suspected or documented intrauterine infection were eligible if they fulfilled the following inclusion criteria: (1) aged 18 years or older; (2) normal renal function; (3) no known allergy to cephalosporin antibiotics; (4) no other pregnancy-related disorders such as hypertension, preeclampsia, and diabetes; and (5) no other medications. These women were treated with 1 g of ceftazidime plus 1 g of amoxicillin, both administered intravenously as a bolus every 6 hours. At delivery, 1 blood sample was taken from the maternal cubital vein and from the umbilical vein of each mother-infant pair.
Sample Handling and Analysis
Serum samples were obtained after centrifugation (Merck type Eppendorf 5414; 3,000g for 1 min) and stored at -70°C until further analysis. Ceftazidime concentrations in maternal and umbilical vein serum were determined using high-performance liquid chromatography according to the method described by Ayrton 17 with minor modifications as described previously. 12, 18 Briefly, 50 μL of 6% (vol/vol) perchloric acid containing 50 mg/L of cephaloridine as an internal standard was added to a 50-μL aliquot of the serum sample. After centrifuging the samples at 1550g for 5 minutes, 25 μL of the supernatant was injected into an high-performance liquid chromatography guard column through an automatic sample injector (WISP 710 B; Waters, Rochester, Minnesota). A glass-prepacked C 18 column (100 × 8 mm, Resolve Radial Pak; Waters) was used for chromatographic analysis. The mobile phase was composed of 4.8% (vol/vol) acetonitrile and 13.5% methanol in 20 mM of sodium acetate buffer (pH 3.6) and was delivered at a flow rate of 2 mL/min by a Waters model 6000 chromatography pump. The sample analytes were quantified using 2 absorbance detectors (model 440/wavelength 254 nm and model 484/wavelength 265 nm; Waters Chromatography). All chemicals were purchased from Aldrich-Chemie (Steinheim, Germany), except high-performance liquid chromatography-grade acetonitrile, which was purchased from Rathbum (Walkerbum, Scotland), and were of the highest grade commercially available. All steps of sample handling and analysis were carried out at room temperature. A linear calibration curve over a range of 4 to 400 μg of ceftazidime per milliliter was obtained through dissolving 4, 12, 25, 50, 100, 200, and 400 μg of ceftazidime per milliliter in serum and processing these spiked samples as described above. Because the spiked samples were analyzed according to the same procedure as the clinical samples, the latter were directly converted to actual ceftazidime concentrations in the serum. The lower limit of detection of ceftazidime in the serum samples was 0.5 mg/L. The inter-and intra-assay coefficients of variation at different concentrations were <7% and <5%, respectively. Recovery of ceftazidime, which had been incubated for 24 hours at room temperature, was 95%.
Modeling the PK Behavior of Ceftazidime in the Mother and Preterm Neonate To describe maternal ceftazidime serum concentrations, a 2-compartment model with linear elimination was used. A 2-compartment model structure was chosen because a previous study used that model structure to describe ceftazidime PK in adults. 19 The ordinary differential equations for the change of drug amount (A) over time (t) are as follows:
Here, A 1 and A 2 represent the drug amount in the central and peripheral compartment, respectively; k 12 and k 21 are the first-order transfer rates from the central to peripheral compartment and vice versa, respectively; k 10 is the first-order elimination rate constant; and I n(t) represents the drug administration. In application of the model, the mass transfer between the central and peripheral compartments was expressed using the intercompartmental exchange rate (Q), clearance (C L), and central V 1 and peripheral V 2 volume of distribution. More precisely, k 12 
were used. The model was parameterized in terms of a previously published model for ceftazidime in adults. 19 Because this parameterization slightly overpredicted observed maternal serum concentrations in the terminal phase, the reported value for clearance was increased based on the following reason: Since ceftazidime is exclusively cleared via glomerular filtration, 11 renal clearance can be estimated as product of glomerular filtration rate and fraction unbound. Using typical prepregnant and pregnant values for the glomerular filtration rate 20 and a previously presented approach for scaling the fraction unbound from nonpregnant to pregnant women, 21 the ceftazidime clearance was increased by 39% at gestational week 30 compared to nonpregnant individuals. Hence, the clearance value reported by Muller and colleagues 19 for nonpregnant adults (6.47 L/h) was increased to 9.0 L/h.
To characterize ceftazidime PK behavior in preterm neonates at delivery, equations 1 and 2 were extended by a third compartment (A 3 ) representing neonatal drug amount:
where k 30 is the neonatal elimination rate constant. Neonatal ceftazidime concentration was modeled with a first-order inflow term from the maternal compartment and a first-order outflow term. More precisely, it was assumed that maternal ceftazidime concentration drives the neonatal concentration in order to not modify the original maternal model, equations 1 and 2. It was observed that a typical constant first-order transfer rate k 13 from the maternal to neonatal compartment was not flexible enough to adequately describe the observed drug PK in the neonate. Therefore, more flexible functions were employed to describe k 13 , and a time-dependent power function with 2 parameters (g, h) was best suited to describe neonatal drug PK:
where TAD is the specific time point of the equidistant administrations. Hence, after every administration k 13 behaves equivalently. Parameters g and h control the shape of the power function. Depending on their values, the rate k 13 either exponentially decreases (as needed in our case) or increases over time. More precisely, after administration of a dose, the transfer from the maternal to neonatal compartment decreases for evolving time until the next administration. The volume of distribution (V 3 ) for this compartment was proportionally scaled to each neonate using the reported fraction of V 1 of total adult weight 19 and the specific birth weight of the neonate. Hence, the drug concentration in the neonate (C) reads
where BW denotes the body weight of the neonate. The final model is given by equations 1 through 5. In this model, 3 parameters were estimated (g, h, and k 30 ) and log-normally distributed interindividual variability was added on parameter g. Residual variability was modeled using a proportional error term. Model equations 1 through 5 are visualized in Figure 1 . PK parameters were estimated using The Monolix Suite 2016R1 (Lixoft; Orsay, France).
Results

Subject Characteristics
Ten pregnant women and their preterm neonates were investigated in this study. The gestational age of these women ranged from 26.3 to 33.6 weeks (mean, 29.1 weeks) and the birth weight of the neonates ranged from 765 to 2190 g (mean, 1310 g). Paired maternal and umbilical vein blood samples were taken between 10 and 330 minutes after the last administration of ceftazidime. Maternal serum concentrations of ceftazidime varied between 5.0 and 43.9 mg/L and umbilical vein serum concentrations between 8.2 and 32.4 mg/L. Three of the women had culture-proven intrauterine infection with E. coli, Neisseria gonorrhoeae, and Listeria monocytogenes. The newborns of these women were infected with the same pathogens and were born 2 to 5 hours after the first dose of ceftazidime. These 3 mother-infant pairs were studied after the first dose of ceftazidime. The remaining women and preterm neonates were studied after having received at least 3 doses of ceftazidime and were presumed to be in 
0 steady state in view of the short half-life of ceftazidime. Among the 10 preterm neonates, 8 received mechanical ventilation. The full subject characteristics as well as the measured ceftazidime concentrations in maternal and umbilical vein serum are given in Table 1 .
Pharmacokinetic Analysis
The final model, equations 1 through 5 ( Figure 1 ), was used to describe the maternal and umbilical vein plasma concentration data. The maternal substructure of this model was parameterized in terms of a previously published model for ceftazidime in adults 19 with a minor modification of the clearance. Estimated parameters of the model, equations 1 through 5, are summarized in Table 2 . Based on these estimates, secondary PK parameters were calculated. Table 3 compares these parameters for the mother and the neonate.
The population prediction of ceftazidime concentrations in the mother and preterm neonates are shown together with the observed data in Figure 2 . As can be seen in this figure, ceftazidime population concentrations in the umbilical cord rapidly reach those in the maternal plasma. Figure 3 depicts the individual predictions in the umbilical vein of the preterm neonates along with the simulated plasma concentrations in the mother. Ceftazidime PK in the maternal plasma and the umbilical vein following different doses assuming dose proportionality in mother and neonate are shown in Figure 4 .
Interpretation of the Power Function. The timedependent inflow rate k 13 (t) in equation 4, describing the transition from maternal to neonatal compartment, generates a nonautonomous ordinary differential equation system. Such time-dependent rates occasionally become necessary, if some underlying phenomena cannot be represented by standard linear approaches. 22 The power function, equation 4, can be equivalently rewritten as a differential equation, that is, a 1-compartment model of the form
Equation 6 shows that g can be interpreted as classical rate constant, and the initial condition k 0 13 depends on both parameters. More precisely, k 13 starts with the value g h and because the parameter estimate of g is smaller than 1 (compare Table 2 ) decreases exponentially over time. Using the equivalent formulation, equation 6, instead of equation 4 reveals that the model, equations 1 through 4, is a nonlinear ordinary differential equation system due to the multiplication of k 13 with A 1 in equation 3. Hence, data and consequently our modeling approach suggest a certain nonlinear behavior between mother and fetus.
Sensitivity Analysis of Model Parameters.
To assess quality of convergence, final parameter estimates (see Table 2 ) were 50 times randomly varied up to 67%. Those perturbed parameters were used as initial estimates, and data were refitted for each case. The elimination rate k 30 was stable with a mean 0.38 (±0.026) and extreme values [0.32, 0.42]. Parameters g and h were associated by the relationship shown in the initial condition from equation 6, and the resulting initial condition x 0 was stable with a mean 0.075 (±0.009). Further, the initial parameter estimates from Table 2 were used, and 1 parameter was strongly modified up to multiple factors. Refitting of the data always resulted in final parameter estimates very close to the results in Table 2 .
Discussion
There is an unmet need of improving evidence-based therapy of infections in pregnant women. Ceftazidime is a commonly used antibiotic against various infections in pregnant women. Although it is considered relatively safe for use in pregnancy, the perinatal PK of ceftazidime in the mother and preterm neonate is not fully understood.
Using sparse data collected at delivery from the mother and preterm neonate, a PK model was developed to describe maternal and neonatal disposition. This model was constructed by extending a previously presented model for nonpregnant adults 19 with an additional compartment representing the neonate. The maternal submodel was connected with the neonatal compartment in a unidirectional way; that is, the maternal drug concentration drives the neonatal concentration. No backflow of ceftazidime from the neonate to the mother was included, and the maternal model structure was also not altered by an outflow term, because such interventions would influence maternal model prediction. Furthermore, this would also entail reestimating the maternal model parameters, which is difficult due to the sparse data situation and the 2-compartment model structure. It was assumed that for maternal disposition predictions the missing backflow from the fetus to the mother can be neglected. In fact, the fraction of the ceftazidime dose transferred to the neonatal compartment was very low. While the presented model does not allow a stoichiometric estimation of the drug molecules transferred to the fetus, the average peak amount of ceftazidime in the fetus was 1.6% of the drug amount administered to the mother. This shows that the drug amount in the neonate available for backflow to the maternal organism is very small and thereby probably insignificant for predictions in the mother.
The previously reported value for the maternal clearance was increased by 39% to reflect pregnancy-induced changes in the glomerular filtration rate and the fraction unbound of ceftazidime. The increase in clearance significantly improved characterization of the herein reported data by the maternal submodel. In contrast to clearance, the central volume of distribution could also have been changed to improve the model. While body weight and composition substantially change during pregnancy, it is much more complex to scale them in a nonmechanistic model. Furthermore, the body weight of the adult subjects involved in the previous study was reported to be 72.3 kg, 19 which corresponds roughly to the body weight of a typical pregnant woman at 30 weeks' gestation. 20 Therefore, it was decided to scale the clearance while keeping the central volume constant.
Ceftazidime distribution to the neonate had to be described by an artificial mathematical function, equation 4. The rationale for this function was that the input signal from the mother, that is, the time-specific drug amount in the central compartment of the mother, had to be compressed and toned down in order to estimate reasonable neonatal clearance values. A typical firstorder rate constant for k 13 was not flexible enough to adequately describe neonatal drug disposition. Instead, a time-dependent power function was constructed, which is difficult to interpret in a physiological manner, but from a mathematical perspective introduces a certain degree of nonlinearity to the model. A firstorder intercompartmental drug exchange rate may be considered, reflecting drug transport via the blood flow to the organ and back to the central blood pool. The fact that k 13 could not be expressed as a firstorder rate constant might indicate that the blood flow to the placenta is not the sole process important for the drug transfer to the fetus and that, for example, permeability limitations also play an essential role. However, it remains a limitation of this study that k 13 is difficult to interpret in a physiological manner. A purely physiological description of placental transfer could be obtained through a physiologically based pharmacokinetic (PBPK) modeling framework. Being mechanistic in nature, PBPK models readily provide a physiological basis of the integrated model parameters. While a physiological interpretation of model parameters is generally desirable, the development of a PBPK model can be time consuming, as it requires a breadth of a priori information. Furthermore, the prediction of placental drug transfer in a PBPK framework is difficult if there is no prior information on the transfer kinetics available (eg, information obtained from ex vivo cotyledon perfusion studies). While the herein presented transfer rate constant k 13 lacks a clear physiological underpinning, it provides a construct that can be readily used for describing placental transfer kinetics that may even be applicable to other cephalosporins or other drug classes (although the specific parameter values may change, of course). In this way, k 13 could be used to rapidly construct a PK model on the basis of sparse data, without the need to integrate a large amount of prior information in a PBPK framework.
The obtained results demonstrate that ceftazidime disposition in the mother and its preterm neonate at delivery is fairly similar. In fact, many PK parameters for the mother are in close agreement to that estimated for the neonate (Table 3 ). In general, neonatal exposure to ceftazidime was comparable to maternal exposure. As expected, the volume of distribution of the central compartment was higher in the mother compared to the neonate, and also when normalized to body weight, neonatal volume of distribution was higher compared to that of the mother (0.320 vs 0.405 L/kg). In the neonate, the extracellular water fraction of total body weight is higher compared to the mother. 20, 23 Because ceftazidime distribution is mainly confined to the extracellular water, 6,7 the higher volume fraction of watery compartments in the fetal/neonatal organism corresponds to a dilution effect, which can explain the higher weight-normalized volume of distribution. Apart from that, an increase in the fraction unbound can also result in an elevated weight-normalized volume of distribution. However, if constant binding capacity is assumed, the fraction unbound is unlikely to be higher in the neonate compared to the mother because neonatal albumin concentration reaches maternal levels by gestational week 30 and exceeds maternal levels thereafter. 24 The results in Table 3 further show that the estimated elimination rate constant and the weightnormalized clearance of the neonate were very similar to those estimated for the mother (elimination rate constant, 0.37 h −1 in the preterm neonate vs 0.39 h −1 in the mother; clearance normalized to body weight, 2.47 mL/min/kg in the preterm neonate vs 2.07 mL/min/kg in the mother). Owing to the missing backflow from neonate to mother, the estimated elimination rate constant in the neonate can be interpreted as a lumped parameter containing both elimination and back distribution to the mother. Ceftazidime accumulation does not appear to occur in the preterm neonate, at least not after the 3 subsequent doses investigated here, and ceftazidime concentrations in the neonate approach those in the mother at steady state (Table 1) . It can therefore be expected that ceftazidime PK in the preterm neonate is similar to that in the mother because the placenta is permeable for ceftazidime and because the mother clears much of the drug for the fetus or neonate at the time of delivery. The estimated value for the neonatal elimination rate indicates that the back transfer of ceftazidime to the maternal organism is rather low because the estimated value is close to that of the mother. The absolute clearance in the preterm neonate, the glomerular filtration rate, is approximately 46-fold lower when compared to maternal clearance (3.23 vs 150 mL/min). This corresponds approximately to the difference between the kidney volume and renal blood flow of the mother and preterm neonate at gestational week 30 on the first postnatal day (kidney volume, 0.610 vs 0.015 mL in the mother and neonate, respectively, corresponding to a 41-fold difference; renal blood flow, 1.5 vs 0.046 L/min in the mother and neonate, respectively, corresponding to a 33-fold difference). 20, 21, 23 This indicates that the lower absolute ceftazidime clearance in the preterm neonate at delivery is probably caused by the lower kidney volume (or glomeruli count) and reduced renal blood flow.
It should be noted, though, that the absolute clearance value used in the maternal submodel (9.0 L/h) is probably, to some extent, too high compared to physiological values. Hence, the difference between maternal and neonatal clearance might be slightly smaller in reality. Since, in adults, ceftazidime is exclusively cleared via glomerular filtration, the absolute clearance of ceftazidime can be expressed as product of the glomerular filtration rate and fraction unbound of ceftazidime. Assuming a fraction unbound of 0.79 8 results in a glomerular filtration rate of 190 mL/min (glomerular filtration rate estimated as C L/0.79), which is slightly higher than the typical value of 150 mL/min, but still within the range of observed values around gestational week 30 (the standard deviation around this week is 29.3 mL/min and the range of reported values varies from 103 to 227 mL/min). 20 Yet a slight reduction of the maternal clearance value used in the presented PK model does not compromise the previously discussed conclusion that the lower ceftazidime clearance in preterm neonates compared to their mothers is mainly caused by the smaller volume of distribution of the latter.
The presented results also show that ceftazidime transfer across the placenta is rapid. High concentrations of ceftazidime were observed as early as 10 minutes after administration and exceeded maternal plasma concentrations thereafter (Table 1) . Ceftazidime is a hydrophilic, zwitterionic compound with moderate molecular weight (547 g/mol). These physicochemical properties impede passive diffusion over the placenta, although they might not preclude it. 25 Active transport of ceftazidime across the placenta has not yet been observed. Ceftazidime is probably a substrate of the organic cation/carnitine transporter-2 26 and multidrug resistance-associated protein-4 (MRP-4), 27 both of which are expressed in the apical membrane of the trophoblasts in the placenta. 28, 29 While there is some evidence that MRP-4 functions as an efflux transporter, 29 organic cation/carnitine transporter-2 has been observed to be an influx transporter facilitating the transfer of substances from the maternal to the fetal side. 28, 30 Provided that passive transplacental diffusion of ceftazidime is low, the herein presented results suggest that active transport from the mother to the fetus plays an important role in ceftazidime disposition during late pregnancy.
In this study, ceftazidime was coadministered with amoxicillin, which were both administered intravenously every 6 hours. Little is known about synergistic or adverse interactions between these 2 drugs. While a synergistic interaction between ceftazidime and liposome-coencapsulated gentamicin has been observed in rats, 31 it has not been investigated for the combination of ceftazidime and amoxicillin. Information on the potential of adverse drug interactions between ceftazidime and amoxicillin is also lacking to date. However, such an adverse drug interaction is unlikely to be clinically significant because of predominantly different elimination routes of both drugs. While ceftazidime is exclusively cleared via glomerular filtration in adults, 11 amoxicillin clearance via glomerular filtration constitutes only ß31% of the total clearance with tubular secretion accounting for ß54% and biotransformation to penicilloid acid for ß15% of the total clearance. 32, 33 These figures suggest that an interaction in the elimination pathways of both drugs is unlikely. However, it should be acknowledged that a potential interaction between ceftazidime and amoxicillin cannot be ruled out on the level of distribution processes. Ceftazidime has been suggested to be a substrate for MRP-4, 27 an efflux transporter expressed in many tissues including the placenta. Previous studies in rats have demonstrated that the glucose-dependent transport of amoxicillin across the jejunum can be completely abolished by benzbromarone, 34 an unspecific MRP inhibitor. Although benzbromarone inhibits multiple MRP isoforms, it cannot be ruled out at this point that MRP-4 is responsible for the secretory transport of both ceftazidime and amoxicillin, thereby bearing the possibility of amoxicillin interfering with the placental efflux of ceftazidime. Future research could explicitly address this question.
While the presented PK model constitutes a useful tool for investigating ceftazidime disposition prior to delivery, its value could be strengthened by incorporating potential drug recirculation between the fetus and the amniotic fluid. Since ceftazidime is excreted in its unchanged form, swallowing of amniotic fluid by the fetus may lead to drug accumulation in the long term. To validate such a model, amniotic fluid samples are necessary, which may be difficult to obtain, and therefore recirculation was not implemented in the model. Given the fact that ceftazidime is repeatedly administered (commonly every 6 hours), accumulation in the fetus might occur. Owing to the lack of in vivo data, recirculation of ceftazidime between the fetus and amniotic fluid and subsequent drug accumulation is not accounted for by the herein presented model, representing a limitation of this study. With respect to drug safety, ceftazidime accumulation is unlikely to present a risk to the fetus; a population-based, casecontrol study did not detect an increased frequency of congenital abnormalities among fetuses or neonates born to mothers treated with cephalosporin antibiotics compared to a control group. 35 However, regarding drug efficacy, ceftazidime concentrations in the fetus and amniotic fluid can matter because the latter may be the target side of action and because the infection may spread to the fetus requiring adequate antibiotic concentrations in the fetal body. Therefore, the presented PK model provides a basic framework that can be extended to evaluate and optimize fetal drug therapy in utero.
Conclusion
The presented results show that ceftazidime readily crosses the placenta achieving comparable concentrations in the umbilical vein compared to the mother. The results further suggest that the lower neonatal ceftazidime clearance stems, in mathematical terms, from the reduced neonatal volume of distribution and, in physiological terms, probably from the reduced number of glomeruli count and renal blood flow of the preterm neonate. The presented PK model provides a useful tool to investigate the effect of different ceftazidime dosing regimens on maternal and preterm neonatal drug exposure at delivery. It further represents a practical framework to develop more complex models that account for the achieved drug concentrations in the amniotic fluid. Yet to develop such a model, in vivo samples from the amniotic fluid are required, which was beyond the scope of this study. In conclusion, clinicians should be aware that PK of ceftazidime in preterm neonates immediately after birth can be expected to be similar to those observed in their mothers.
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